To improve outcomes for patients with non-small-cell lung carcinoma researchers are developing a blood test to detect lung cancer earlier in the disease. A report describes a new technology, electric field-induced release and measurement (EFIRM) that is both highly sensitive and specific in detecting two epidermal growth factor receptor (EGFR) mutations associated with lung cancer in the blood of NSCLC patients with early-stage disease. This platform is relatively inexpensive and capable of high-throughput testing.